• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Crescent Biopharma Inc.

    4/21/26 4:18:40 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CBIO alert in real time by email
    DEFA14A 1 defa14-2026proxystatementx.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ________________
    SCHEDULE 14A
    ________________
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No. )
    ________________
    Filed by the Registrant
    ☒
    Filed by a Party other than the Registrant
    ☐
    Check the appropriate box:
    ☐
    Preliminary Proxy Statement
    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐
    Definitive Proxy Statement
    ☒
    Definitive Additional Materials
    ☐
    Soliciting Material under § 240.14a-12
    CRESCENT BIOPHARMA, INC.
    (Name of Registrant as Specified In Its Charter)
    _________________________________________________________________
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
    ☒No fee required.
    ☐
    Fee paid previously with preliminary materials.
    ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.






    preferred1a.jpg




    preferred2a.jpg

    Get the next $CBIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CBIO

    DatePrice TargetRatingAnalyst
    6/1/2026Buy → Neutral
    H.C. Wainwright
    1/28/2026$35.00Overweight
    Piper Sandler
    1/21/2026$35.00Buy
    Guggenheim
    8/25/2025$26.00Buy
    Jefferies
    8/11/2025$25.00Buy
    H.C. Wainwright
    7/14/2025$27.00Outperform
    Wedbush
    6/25/2025$28.00Buy
    Stifel
    11/15/2021Outperform → Market Perform
    Raymond James
    More analyst ratings

    $CBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Crescent Biopharma to Present at June Investor Conferences

    WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in June: 2026 Jefferies Global Healthcare Conference, fireside chat on Wednesday, June 3, 2026 at 4:20 p.m. ET in New YorkGoldman Sachs 47th Annual Global Healthcare Conference, fireside chat on Monday, June 8, 2026 at 8:40 a.m. ET in Miami A live webcast of each presentation will be available in the Investors section of Crescent's website at https://investors.c

    6/2/26 4:15:00 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crescent Biopharma Announces Grants of Inducement Awards

    WALTHAM, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 16,950 shares of the Company's ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the "Inducement Plan"). The options were approved on May 28, 2026 and were material to each employee's acceptance o

    5/29/26 4:15:00 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

    ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multiple CR-001 clinical data readouts anticipated beginning in Q1 2027 Waltham, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced a trial in progress poster of the ASCEND study of CR-001, a PD-1 x VEGF bispecific antibody, will be presented during the 2026 American Society of Clinical Oncology (ASCO) Annu

    5/21/26 5:30:00 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBIO
    SEC Filings

    View All

    Crescent Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)

    6/3/26 9:02:51 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Crescent Biopharma Inc.

    SCHEDULE 13G/A - CRESCENT BIOPHARMA, INC. (0001253689) (Subject)

    5/15/26 4:15:13 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Crescent Biopharma Inc.

    SCHEDULE 13G - CRESCENT BIOPHARMA, INC. (0001253689) (Subject)

    5/15/26 6:31:14 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Crescent Biopharma downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Crescent Biopharma from Buy to Neutral

    6/1/26 8:47:44 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Crescent Biopharma with a new price target

    Piper Sandler initiated coverage of Crescent Biopharma with a rating of Overweight and set a new price target of $35.00

    1/28/26 7:10:21 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Crescent Biopharma with a new price target

    Guggenheim initiated coverage of Crescent Biopharma with a rating of Buy and set a new price target of $35.00

    1/21/26 8:54:45 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Violin Jonathan

    4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)

    6/3/26 7:48:33 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lubner David Charles

    4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)

    6/3/26 7:48:11 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Balcom Alexandra

    4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)

    6/3/26 7:47:50 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairmount Funds Management Llc bought $18,237,600 worth of Ordinary Shares (1,360,000 units at $13.41) (SEC Form 4)

    4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)

    12/8/25 4:30:15 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

    Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation Therapeutics for Solid Tumors WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the appointment of Jan Pinkas, Ph.D., as chief scientific officer. Dr. Pinkas brings more than two decades of experience in oncology drug development, leading preclinical and translational research with expertise in multiple modalities, including antibody-drug conjugates (ADCs). "We are thrilled to welcome Ja

    7/8/25 7:30:00 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

    EMERYVILLE, Calif., Dec. 15, 2023 /PRNewswire/ -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced today that Nassim Usman, Ph.D., has been named President & Chief Executive Officer and closed a $66M Series B financing led by DCVC Bio. Neil Dhawan, Ph.D, Totus co-founder, founding CEO, and CSO, will transition into a new role as CSO and Head of R&D, where he will continue to oversee the company's platform, programs, and data. "We are thrilled by Nassim's arrival," said DCVC Bio Managing Pa

    12/15/23 9:04:00 AM ET
    $CBIO
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Biosciences Sends Letter to Stockholders

    Reiterates the Board's Commitment to Expeditiously Distributing All of the Company's Available Cash to Stockholders, Net of Liabilities and Obligations Warns Stockholders that JDS1 May Have Ulterior Motives in Running a Proxy Contest: Gaining Control of the Company's Cash and Other Assets for JDS1's Own Benefit Stockholders Urged to VOTE "FOR" ALL of Catalyst's Nominees, Who Are Committed to the Company's Cash Distribution Plan, on the WHITE Proxy Card SOUTH SAN FRANCISCO, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the "Company" or "we") today announced that it mailed a letter to its stockholders in connection with the Company's upcoming 2022 Ann

    7/19/22 8:00:00 AM ET
    $CBIO
    $EVOL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    EDP Services
    Technology

    $CBIO
    Financials

    Live finance-specific insights

    View All

    Catalyst Biosciences Completes First Steps in Reverse Merger Plan

    Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 Million Special Dividend and Contingent Value Right (CVR) CBIO Stockholder Meeting Planned for 2023 CBIO to Host Conference Call Today at 8:00 a.m. E.T. SOUTH SAN FRANCISCO, Calif. and TOKYO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst") and GNI Group Ltd. (2160.T) ("GNI") today announced that the parties have signed definitive agreements for the sale and purchase of GNI's proprietary new chemical entity F351 program. F351 has shown clinical efficac

    12/27/22 7:00:00 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share

    SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst," the "Company" or "we") today announced that the ex-dividend date for the special, one-time cash dividend of $1.43 per share to holders of the Company's Common Stock previously disclosed by the Company will be September 21, 2022. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. Stockholders of record on the record date who sell their shares prior to the ex-dividend date will not receive the special dividend. The aggregate amount of the payment to be made in connection with this special dividend will be app

    9/1/22 4:05:00 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share

    SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst," the "Company" or "we") today announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per share to holders of the Company's Common Stock. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. The aggregate amount of the payment to be made in connection with this special dividend will be approximately $45 million. The Company anticipates that it may declare one or more additional special dividends in the future, although there can be no assurance that such distributions will

    8/25/22 8:00:00 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Catalyst Biosciences Inc. (Amendment)

    SC 13G/A - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

    2/14/24 1:18:41 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Catalyst Biosciences Inc. (Amendment)

    SC 13D/A - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

    1/24/24 5:11:14 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Catalyst Biosciences Inc. (Amendment)

    SC 13D/A - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

    11/27/23 4:49:38 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care